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Abstract
Background: The use of retinoids as anti-cancer agents has been limited due to resistance and
low efficacy. The dynamics of nuclear receptor coregulation are incompletely understood. Cell-and
context-specific activities of nuclear receptors may be in part due to distinct coregulator
complexes recruited to distinct subsets of target genes. RIP140 (also called NRIP1) is a liganddependent corepressor that is inducible with retinoic acid (RA). We had previously shown that
RIP140 limits RA induced tumor cell differentiation of embryonal carcinoma; the pluriopotent stem
cells of testicular germ cell tumors. This implies that RIP140 represses key genes required for RAmediated tumor cell differentiation. Identification of these genes would be of considerable interest.
Results: To begin to address this issue, microarray technology was employed to elucidate in a de
novo fashion the global role of RIP140 in RA target gene regulation of embryonal carcinoma.
Subclasses of genes were affected by RIP140 in distinct manners.
Interestingly, approximately half of the RA-dependent genes were unaffected by RIP140. Hence,
RIP140 appears to discriminate between different classes of RA target genes. In general, RIP140dependent gene expression was consistent with RIP140 functioning to limit RA signaling and tumor
cell differentiation. Few if any genes were regulated in a manner to support a role for RIP140 in
"active repression". We also demonstrated that RIP140 silencing sensitizes embryonal carcinoma
cells to low doses of RA.
Conclusion: Together the data demonstrates that RIP140 has profound effects on RA-mediated
gene expression in this cancer stem cell model. The RIP140-dependent RA target genes identified
here may be particularly important in mediating RA-induced tumor cell differentiation and the
findings suggest that RIP140 may be an attractive target to sensitize tumor cells to retinoid-based
differentiation therapy. We discuss these data in the context of proposed models of RIP140mediated repression.
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Background
Retinoids are used in the clinic to prevent and treat select
tumors through the process of induced tumor cell differentiation, yet the efficacy of retinoids toward the most
common neoplasms has been limited [1]. Therefore, it is
important to understand the mechanisms by which
tumors are resistant to the ability of retinoids to affect
tumor growth and progression. Embryonal carcinoma
(EC) is a model of embryonic development as well as
tumor cell differentiation [2]. EC is considered to be the
malignant counterpart to embryonic stem cells because of
a remarkable degree of genetic, morphologic, biochemical
and gene expression similarity [3,4]. EC cells are pluripotent and considered to be the stem cells of male germ cell
tumors [3,4]. In response to all trans retinoic acid (RA),
the pluripotent human EC cell line, NT2/D1, differentiates toward a neuronal lineage with associated loss of cell
growth and tumorigenicity [5,6].
Retinoids mediate their effects by binding to and activating retinoid specific nuclear receptors, RARs and RXRs
[7,8]. Corepressors, such as NCoR and SMRT, bind to
nuclear receptors in the absence of ligand to assemble
large repressor complexes containing chromatin repressing and histone deacetylase activity [9,10]. Ligand-bound
receptors recruit coactivators, such as the p160 family,
which recruit histone acetyltransferases and other chromatin remodeling proteins to induce gene transcription
[11].
This classic coregulator paradigm does not fully explain
the recent evidence that ligands such as retinoids, estrogen, and vitamin D3, apparently also actively suppress
gene expression [12,13]. These data challenge the current
coregulator paradigm by implying that repressor complexes may participate in active repression of ligandbound receptors. RIP140 is the first member of a unique
class of ligand-dependent corepressors [14-18]. RIP140
exhibits intrinsic repression activity when fused to the
Gal4-DNA binding domain, and directly recruits histone
deacetylases as well as the transcriptional repressor, c-terminal binding protein (CTBP), to nuclear receptors
[19,20]. In addition, RIP140 inhibits the transactivation
function of several ligand bound nuclear receptors [1418]. Since RIP140 preferentially binds and suppresses
agonist bound nuclear receptors, it provides a candidate
mechanism for active repression of several members of
the nuclear receptor superfamily.
Our prior work demonstrated that RIP140 is a direct target
of retinoid signaling and that RIP140 can be limiting for
both retinoid and estrogen signaling [21-23]. Silencing
RIP140 in NT2/D1 cells resulted in RA-dependent
increases in expression of model endogenous RA target
genes RARβ and LEFTY2, and enhanced and accelerated
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RA-induced differentiation and growth suppression [22].
This evidence suggests that RA induction of RIP140 constitutes a negative-feedback mechanism to fine-tune retinoid signaling.
Retinoids are pleiotropic agents regulating many gene targets. However, we have shown that RIP140 siRNA accelerates
RA-dependent
growth
suppression
and
differentiation [22]. The identification of genes normally
limited by RIP140 during RA-induced growth and differentiation is of interest since these genes may be particularly important regulators of these processes. The
possibility remains that unidentified subclasses of genes
may be regulated by RIP140 in distinct manners [22].
The present study was conducted to characterize, on a
genome-wide scale, the role of RIP140 in the regulation of
RA signaling in a cancer stem cell model. Together the
data demonstrates that RIP140 has profound effects on
RA-mediated gene expression. Subclasses of genes were
affected by RIP140 in distinct manners while other RAdependent genes were unaffected suggesting that RIP140
may discriminate between different classes of RA targets.
The RIP140-dependent RA target genes identified here
may be particularly important in mediating RA-induced
tumor cell differentiation.

Results
Validation of RIP140 specific siRNA
We previously established that RIP140 is a target of RA signaling and that RIP140 in turn is a limiting factor for RA
activity [22]. Specifically, we showed that knockdown of
RIP140 with a RIP140-specific siRNA (RIP140siRNA#1)
increased endogenous expression of RA target genes RARβ
and LEFTY2, and accelerated immunophenotypic differentiation as measure by A2B5 staining of NT2/D1 cells
[22]. A key feature was that knockdown of RIP140 did not
affect these endpoints in cells depleted of endogenous
retinoids, confirming that RIP140 mainly associates with
ligand-bound nuclear receptors. These studies were performed with a constant 1 µM dose of RA and a relatively
high, 150 nM dose of siRNA. Prior to global gene expression studies, we wished to further validate the siRNA
approach for targeting RIP140.

Experiments were performed under charcoal absorbed
sera conditions to deplete the basal levels of retinoids
known to be in sera. An additional siRNA,
RIP140siRNA#2, also potently enhanced the RA-mediated expression of the RA target gene RARβ at 150 nM and
at doses as low as 40 nM (Figure 1A). Importantly, RIP140
siRNA cells also overexpressed RARβ when compared to
mock transfected cells (Figure 1A). Low, 40 nM doses of
RIP140siRNA#1 and RIP140siRNA#2 resulted in
enhanced neuronal differentiation with RA as assessed by
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expression of the early neuronal ectodermal marker, A2B5
(Figure 1B).

percentage of direct RA-target genes could be expected to
be uncovered compared to later time points.

An important control to ensure a given siRNA phenotype
is not due to off-target effects is to rescue the siRNA phenotype with overexpression of its target. RIP140siRNA#1,
as well as a newly designed siRNA targeting the 3' untranslated region of human RIP140 (siRNA#3) enhanced
induction of a RAR-specific reporter construct in a RAdependent manner (Figure 1C). Further, a RIP140 expression plasmid that does not contain the 3' untranslated
region of RIP140 repressed RA signaling in scrambled
control cells (Figure 1C). This RIP140 construct potently
opposed the effect of RIP140siRNA#3 but not
RIP140siRNA#1, which targets the coding region of
RIP140. Thus, silencing of RIP140 by siRNA enhanced
RA-mediated responses in NT2/D1 cells at low doses of
siRNA and this could be rescued by exogenous RIP140.
Further, the effects of RIP140 silencing were mainly ligand-dependent since performing these experiments under
charcoal absorbed sera conditions resulted in minimal
changes in basal RAR activity or in the differentiation of
NT2/D1 cells (Figure 1).

Based on the current understanding of the properties of
RIP140 [14-18], a number of potential outcomes were
anticipated: 1) RIP140 may limit RA target gene activation
by negative-feedback inhibition upon RA addition, 2)
RIP140 may participate in "active repression" of gene
expression upon RA addition, 3) an unexpected outcome
that RIP140 may participate in the activation of a subset
of target genes, 4) RIP140 may regulate the transcription
of target genes of other nuclear receptors or even nonnuclear receptor transcription factors. The readout from
the array design that would support each of these outcomes is depicted in Figure 2B. The extent of RIP140
knockdown and the level of enhancement of RARβ
expression in the actual samples used in for array are
depicted in Figure 2C.

Microarray Design
We then sought to determine the global effects of RIP140
on RA-dependent and RA-independent gene expression. A
dose of siRNA of 90 nM was chosen. Twelve independent
hybridizations were performed from mRNA isolated from
12 independent samples (Figure 2A). One scrambled and
two independent RISC-free siRNA transfections and transfections with three distinct RIP140 siRNAs were performed in NT2/D1 cells. Each siRNA treatment was
further treated with either 10 µM RA or DMSO control for
24 hours. Hence, the design consisted of four groups, the
three siRNA controls treated with vehicle, Group 1; the
siRNA controls treated with RA, Group 2; siRNA to
RIP140 treated with vehicle, Group 3; and siRNA to
RIP140 treated with RA, Group 4 (Figure 2A).

The treatments were done in the presence of normal sera,
since charcoal absorption of sera removes many small
hydrophobic ligands to the nuclear receptor family in
addition to retinoids. This measure was taken with the
aim to perhaps identify target genes of other nuclear
receptors including orphan receptors that could be regulated by RIP140 in the presence of low levels of their cognate ligands. RA treatment of 10 µM for 24 hours was
chosen since previous experience with NT2/D1 cells indicated that a reasonably sized set of altered genes would be
obtained [5,24]. In addition, NT2/D1 cells commit to RAinduced differentiation by 48 hours and RIP140 repression accelerates RA-induced differentiation of EC cells
[5,22]. Therefore, the 24-hour time point is well-within
the range of the RA commitment "window" and a larger

Silencing of RIP140 quantitatively alters the RA
transcriptional response in EC cells
To further ensure that off-target effects were minimized,
any gene that differed 1.5-fold or greater between the replicates of the control (Group 1) were removed from the
analysis. The expression of the remaining 52,270 probe
sets were compared in pairwise fashion between the
experimental groups (Figure 3). As expected, comparison
of gene expression between the siRNA control cells treated
with RA and the control cells treated with vehicle revealed
that the great majority of genes are unaltered with RA
treatment (Figure 3A). Interestingly, the total number of
genes regulated by RA in the RIP140 siRNA cells increased
compared to the number of genes regulated by RA in the
siRNA control cells (compare the spread in the scatter
plots between Figure 3A vs. Figure 3B or 3C). This is
apparent regardless of whether RIP140 siRNA RA cells
were compared with control siRNA vehicle cells (Figure
3B) or compared to RIP140 siRNA vehicle cells (Figure
3C). The disparity in the overall number of RA-sensitive
genes increased as the fold-cut off increased (Figure 3F),
suggesting that RIP140 siRNA increases the number of RA
altered genes and also amplifies RA-dependent gene alterations. It is important to emphasize that the genes identified here under these experimental conditions may not be
direct target genes of liganded RARs. The complete list of
genes and expression values for each pairwise comparison
is supplied in Supplemental Tables S1 to S5 [see Additional file 1].

A similar trend is also apparent in the scatter plot comparing RIP140 siRNA RA cells with control siRNA RA cells
(Group 4 vs. Group 2, Figure 3D). The greatest difference
is in RA induced genes, consistent with a role for RIP140
in repressing the activation of ligand engaged RARs. However, a number of repressed genes are also repressed to a
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Figure silencing
RIP140
1
enhances ligand-dependent RAR activation and tumor cell differentiation
RIP140 silencing enhances ligand-dependent RAR activation and tumor cell differentiation. (A, left) Northern
analysis depicting the effect of RIP140 siRNA on expression of known retinoic acid receptor target gene RARβ in NT2/D1
cells. Cells were mock transfected (no siRNA) or transfected with 150 nM siRNA prior to treatment with 1 µM RA for 24
hours. (A, right) Northern analysis depicting the effect of RIP140 siRNA on expression of RARβ. Cells were transfected with
40 nM siRNA prior to treatment with 1 µM RA for 24 hours. Scbl, scrambled. B) Immunophenotypic FACS analysis for the
established neuroectodermal marker A2B5 in NT2/D1 cells transfected with 40 nM scrambled siRNA (Scbl) or RIP140
siRNA#1 or RIP140 siRNA#2 and treated for 4 days with DMSO vehicle control or indicated dosages of RA. Representative of
two experiments. (C) The effect of RIP140 siRNAs and exogenous RIP140 expression on activity of an RARE-TK-Luc promoter in NT2/D1 cells. Cells were transfected with indicated control (scbl) or RIP140 siRNAs at a concentration of 50 nM and
either empty expression vector or a plasmid expressing RIP140 prior to addition of indicated dosages of RA for 48 hours.
Note, RIP140 siRNA#1 targets sequences within the RIP140 expression plasmid while RIP140 siRNA#3 targets the 3' untranslated region of RIP140 but does not target PSG5-RIP140. Error bars are S.D. of triplicate determinations. For all experiments
above, cells were cultured in charcoal absorbed sera media for 24 hours prior to and during the experiment.
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Figure 2 design
Microarray
Microarray design. (A) Cells cultured in normal sera media were transfected with 90 nM control siRNAs (scrambled or
RISC-free) or three separate RIP140 siRNAs. Cells were than split into DMSO, vehicle treatment or 10 µM RA treatment for
24 hours prior to harvesting for mRNA. (B) Possible outcomes of RIP140 siRNA on RA-dependent and RA-independent gene
expression. -, no change or no expression; ++ or ++++, expression or increased expression. (C) Northern analysis of actual
samples for microarray analysis depicting repression of RIP140 expression with indicated RIP140 siRNA and associated
enhancement of RARβ expression. Included are mock transfected cells (no siRNA).
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Figure plot
Scatter
3 analysis of gene expression differences between groups
Scatter plot analysis of gene expression differences between groups. (AE) The three independent samples for each
of the four groups as outlined in Figure 2A were averaged and then compared to one another utilizing the GeneSifter package
as described in Materials and Methods. Red squares represent genes expressed to a higher degree in samples along the y-axis;
green squares represent genes expressed to a higher degree in samples along the x-axis. Grey squares represent genes
changed less than 1.5 fold or with a p-value that failed to reach 0.05. (F) Table depicting the number of genes in the pairwise
comparisons above (A-E) that are altered above the fold-cut offs indicated and with a p-value < 0.05.
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greater extend in RIP140 siRNA cells, although this differential expression is lower. Table 1 and supplemental Table
S6 [see Additional file 2] list the top genes differentially
expressed between siRNA RIP140 RA cells and control
siRNA RA cells (Group 4 vs. Group 2). Table 1 ranks the
genes by fold-change, while Table S6 [see Additional file
2] ranks the genes by p-value. The known RA-target gene
HOXA5 is induced 1.6 fold with RA in siRNA control cells
and 20.6-fold with RA in RIP140 siRNA cells for a differential induction of 12.8. RARβ, the primary gene used the
establish the negative-feedback model was also identified
as being super-induced by RIP140 siRNA (Table 1). Other
genes that are highly RIP140-dependent in their RA-alterations include both known (MEIS1, HOXB5, HOXB13)
and previously unsuspected (NODAL, TSHZ1) RA target
genes. Other noteworthy genes regulated by RA in a
RIP140-dependent manner include the nuclear receptor
coactivator PCAF and the pluripotency gene FOXD3
which are predicted to be upregulated and downregulated
by RA, respectively (Table 1). Including the previously
confirmed RARβ gene, we were able to confirm the
RIP140-dependent expression pattern of 5 of the top 6
genes from Table 1 (Figure 4).
The majority of RIP140-dependent genes change in a
manner consistent with RIP140 limiting RA signaling.
Hence, RIP140 siRNA results in enhancement or amplification of the RA signal. Genes induced by RA in control
cells are induced to a greater extent by RA in RIP140
siRNA cells and genes repressed by RA in control cells are
repressed to a greater extent in RIP140 siRNA cells. This
trend holds true whether the effects of RIP140 on RA signaling are ranked by fold-change (Table 1, 47 out of 49
genes) or p-value (Table S6, 37 out of 40 genes). The
exceptions are bolded in Tables 1 and Table S6 [see Additional file 2]. In addition only 1 gene in the ranked tables
had an expression profile that could be consistent with
"active repression" (second pattern in Figure 2B). This
gene is boxed in Table S6. The effects of RIP140 had little
bias for the extent of RA-induction. For example, a
strongly induced gene, PYCR2, is induced by RA in control
cells 32.6-fold and in RIP140 siRNA cells by 104.6-fold,
while a weakly induce gene INHBB is induce 1.22-fold in
control cells and 2.95-fold in RIP140 siRNA cells (Table
1). There are also examples of genes that are not altered
with RA in control cells but altered by RA in RIP140 siRNA
cells. One interpretation of this result is that the RA alteration of these genes may have been accelerated with
RIP140 siRNA and that the 24-hour time point is too early
to detect RA-mediated changes in the siRNA control cells.
Silencing of RIP140 does not greatly alter RA-independent
gene expression
Although the array experiments were designed to maximize the potential to find RA-independent RIP140 targets,
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very few genes matching this pattern were found (last pattern in Figure 2B). This is evident by the comparison of
Group 3 vs. Group 1 (Figure 3E, and Table 2 and supplemental Table S7 [see Additional file 3]). Reassuringly, one
of the genes identified by the array as repressed basally is
RIP140 itself. There is a clear bias for repressed genes suggesting that these genes are indirectly regulated by
RIP140. The majority of the altered genes in Figure 3E and
Table 2 and Table S7 are also altered with RA in siRNA
control and RIP140 siRNA cells (Figure 5). Hence, RIP140
siRNA caused basal alterations in some genes that are
altered in control siRNA cells treated with RA. One interpretation of this result is that RIP140 siRNA is sensitizing
the cells to the basal levels of retinoids in the normal sera
media. Two genes that were found to be exclusively
expressed in RIP140 siRNA cells independent of RA, and
hence fit the pattern of RA-independent RIP140 targets
(last pattern in Figure 2B), were doublecortex (DCX,
bolded in Table 2) and reticulon 1 (RTN1, just missed
fold-cutoff in Table 2). Both of these genes have roles in
neuronal development. Interestingly, a third gene that fit
this pattern was only induced 1.47 fold in RIP140 siRNA
cells but had a highly significant p-value, the repressor
protein, c-terminal binding protein 2 (CTBP2) (Table S7).
CTBP2 is a known RIP140 co-factor [20]. This suggests
that RIP140 may repress transcription of its own cofactor.
RA target genes cluster into distinct groups based on
RIP140-dependency
The major influences of RIP140 siRNA were also assessed
by hierarchical clustering. There were 1,115 genes with a
fold change of 1.8 or greater in any of the four groups with
p-value < 0.01 (supplied as Supplemental Table S8 [see
Additional file 4]). These were clustered by the Eisen program (Figure 5). Inspection of the cluster confirms that
the major pattern of RIP140 siRNA alterations is RAdependent. In that, very few genes made to threshold cutoffs because of RA-independent alterations in expression
(only changed in Group 3 and Group 4 of Figure 5). Further, the pattern associated with active repression (Figure
2B) was not greatly evident (would be green in Group 2
but less green in Group 4 of Figure 5). Genes representative of the major patterns are shown in Figure 5. These
include genes that are basally induced or repressed with
RIP140 siRNA, and genes that are "super-induced" or
"super-repressed" by RIP140 siRNA. Approximately half
of the total RA-dependent genes were not influenced by
RIP140 in this analysis. Partitioning around mediods
(PAM) analysis was also performed on genes with a cut off
of 1.5-fold and p-value of < .001, (1065 genes) (Figure 6).
There were 542 genes in cluster patterns indicative of little
or no change with RIP140 siRNA (Cluster 1 and Cluster
2). There were 312 genes in cluster patterns indicative of
super-induction or super-repression with RIP140 siRNA
(Cluster 3 and Cluster 4) and 211 genes in clusters indic-
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Table 1: Genes differentially expressed with RA in RIP140 siRNA treated NT2/D1 cells

Gene symbol

Gene description

HOXA5
TSHZ1
DMRT1
C8orf72
ZADH2
VSNL1
RARB
PYCR2
DEPDC6
KCNJ4
HOXB5
MEIS1

Homeobox A5
Teashirt family zinc finger 1
Doublesex and mab-3 related transcription factor 1
Chromosome 8 open reading frame 72
Zinc binding alcohol dehydrogenase, domain containing 2
Visinin-like 1
Retinoic acid receptor, beta
Pyrroline-5-carboxylate reductase family, member 2
DEP domain containing 6
Potassium inwardly-rectifying channel, subfamily J, member 4
Homeobox B5
Meis1, myeloid ecotropic viral integration site 1 homolog
(mouse)
DKFZP686A01247 hypothetical protein
Phospholipase A2 homolog
Sushi domain containing 3
Endothelial differentiation, lysophosphatidic acid G-protein
recept
Neuropilin 1
Kinesin family member 21B
Inhibin, beta B (activin AB beta polypeptide)
Homeobox B13
Ovostatin 2
Major histocompatibility complex, class II, DP beta 1
Elastin microfibril interfacer 2
Hyaluronan synthase 3
Nuclear receptor subfamily 6, group A, member 1
AT motif binding factor 1
Nodal homolog (mouse)
Zinc finger protein 703
Protocadherin 17
Pregnancy-associated plasma protein A, pappalysin 1
Kelch-like 7 (Drosophila)
Ligand of numb-protein × 1
Protein kinase C, eta
T-box 3 (ulnar mammary syndrome)
Adrenomedullin
Potassium channel tetramerisation domain containing 12
Protein tyrosine phosphatase, receptor type, U
Wingless-type MMTV integration site family, member
3
Mucolipin 3
P300/CBP-associated factor
Hypothetical LOC645323
Endothelial PAS domain protein 1
WD repeat domain 68
Cannabinoid receptor 1 (brain)
Family with sequence similarity 46, member B
Forkhead box D3
PTPRF interacting protein, binding protein 2 (liprin beta 2)
Adenylate kinase 3-like 1
Mitogen-activated protein kinase kinase kinase 5

FLJ12624
SUSD3
EDG7
NRP1
KIF21B
INHBB
HOXB13
OVOS2
HLA-DPB1
EMILIN2
HAS3
NR6A1
ATBF1
NODAL
ZNF703
PCDH17
PAPPA
KLHL7
LNX1
PRKCH
TBX3
ADM
KCTD12
PTPRU
WNT3
MCOLN3
PCAF
LOC645323
EPAS1
WDR68
CNR1
FAM46B
FOXD3
PPFIBP2
AK3L1
MAP3K5

RA fold-change in
control siRNA
cells

RA fold-change
in RIP140 siRNA
cells

Differential
fold-change

p-value

+1.60
+2.15
-1.09
+2.34
+1.48
-3.89
+7.99
+32.66
+2.76
+3.72
+1.40
+3.09

+20.66
+18.87
+3.99
+9.85
+5.67
-14.60
+26.90
+104.63
+8.67
+11.52
+4.19
+9.06

+12.88
+8.76
+4.35
+4.21
+3.84
-3.75
+3.37
+3.20
+3.15
+3.10
+2.99
+2.93

0.000368
0.001052
0.010148
0.022663
0.011172
0.000767
0.012977
0.011152
0.026040
0.008146
0.031222
0.022140

+1.92
-3.20
+3.07
-1.58

+5.28
-8.31
+7.89
-4.02

+2.76
-2.59
+2.57
-2.55

0.006054
0.000778
0.023342
0.019311

+1.54
-1.04
+1.22
+1.21
-1.66
-2.07
-1.65
-1.75
-1.02
+2.93
+1.20
+2.62
+2.71
+1.43
-1.34
-1.13
+1.99
+4.45
-1.15
-1.03
+1.16
+3.05

+3.84
+2.37
+2.95
+2.82
-3.85
-4.79
-3.72
-3.86
+2.17
+6.45
+2.60
+5.67
+5.81
-1.48
-2.81
-2.30
+4.05
+9.01
-2.32
-2.08
+2.32
+1.53

+2.50
+2.46
+2.42
+2.34
-2.32
-2.31
-2.25
-2.21
+2.21
+2.20
+2.16
+2.16
+2.14
-2.11
-2.09
-2.04
+2.04
+2.03
-2.02
-2.02
+1.99
-1.99

0.024092
0.001602
0.001612
0.028115
0.001967
0.048107
0.010781
0.001436
0.014380
0.000101
0.001068
0.046510
0.046724
0.026579
0.039448
0.008236
0.036242
0.046092
0.019731
0.003013
0.006395
0.009256

-1.26
+1.64
+6.84
+1.01
+1.07
+11.84
-3.48
-3.72
-1.17
-4.02
-1.12

-2.48
+3.22
+13.40
-1.93
+2.09
+23.16
-6.81
-7.26
-2.25
-7.69
+1.70

-1.97
+1.97
+1.96
-1.96
+1.96
+1.96
-1.95
-1.95
-1.92
-1.91
+1.90

0.041576
0.017906
0.002997
0.007540
0.000433
0.006641
0.015572
0.018665
0.001765
0.001875
0.020647

Gene list represents genes in scatter plot of Figure 3D; Group 4 (siRNA RIP140 RA) vs. Group 2 (control siRNA RA). Genes with a p-value <
0.05 are ranked by fold change between the expression of Group 4 vs. Group 2 (Differential fold change). Values corresponding to scatter plot
of Figure 3A, Group 2 vs. Group 1 (RA-fold change in control siRNA cells) and scatter plot of Figure 3C, Group 4 vs. Group 3 (RA-fold change
in RIP140 siRNA cells) are also provided. For genes with multiple probe sets, the probe set with the greatest differential expression was chosen.
In bold are the two genes where RIP140 siRNA lessens the extent or direction of RA-mediated regulation.
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ative of basal induction or basal repression in RIP140
siRNA cells (Cluster 5 and Cluster 6, Figure 6). The list of
genes and expression values for each of the six clusters is
supplied as Supplementary Tables S9 to S14 [see Additional file 5]. Genes representative of some of the patterns
were confirmed in independent samples (Figure 7).
Mode of action of RIP140 in RA signaling
The pattern of gene expression in RIP140 siRNA cells suggests that RIP140 siRNA may influence RA signaling in
distinct manners, either to sensitize cells to lowdose RA
(basally altered array genes) or to accelerate or amplify
RA-dependent gene expression (super-induced or superrepressed array genes). However, the array was performed
at a single RA dose and time point. We had shown previously that RIP140 siRNA accelerates and enhances RAinduced differentiation in NT2/D1 cells [22]. RIP140
siRNA was also able to promote differentiation of NT2/
D1 cells at low doses of RA (Figure 8A). Time course studies demonstrated that RIP140 siRNA caused a combination of accelerated and amplified alterations in RA target
gene expression (Figure 8B). Hence, these data suggests
that RIP140 may limit a subset of RA target genes by effecting the rate and extent of target gene expression at a given
dose of RA.

Discussion
Through the use of microarray technology we sought to
elucidate, in a de novo fashion, the global role of RIP140
in RA-dependent signaling. The predominant gene expression pattern is consistent with RIP140 limiting RA signaling [22]. Since RIP140 depletion enhances RA-induced
differentiation (Figure 1B, 8A) these genes may play an
important role in mediating the growth suppression, differentiation and anti-tumorigenic effect of RA in embryonal carcinoma. These data support the notion that the
primary effect of the ligand-dependent corepressor
RIP140 is to limit the activity of retinoid receptors (Figure
8C). A feature of this model is that RIP140 is itself induced
by RA [21] and that RIP140 inhibits ligand-bound RARs
to form a classic negative-feedback loop. One interesting
gene predicted to be repressed by RIP140 was the RIP140
cofactor, CTBP2 [20]. This raises the potential of the additional complexity of RIP140 limiting its own activity by
regulating CTBP2. Confirming and establishing the
importance of RIP140 transcriptional regulation of
CTBP2 will require further rigorous studies.
It is tempting to speculate on the importance of RIP140
restriction of RA-target gene expression. One possibility is
that RIP140 ensures that cells are exposed to a threshold
concentration of RA for a required duration before committing to differentiation. This could be important for
developmental timing but an impediment to retinoid
therapies in the adult [1,25]. Alternatively, RIP40 may
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fine-tune the RA signal to ensure that a critical set of target
genes are not overly or toxically expressed.
Our studies suggest that regulation of RAR signaling by
RIP140 is more complex than a simple all-or-none effect
on global RAR activation. We have identified gene subsets
regulated by RA in apparent RIP140-dependent and
RIP140-independent manners. It is possible that RIP140
may have a selective ability to affect the actions of different subtypes of retinoid receptors. Alternatively, this differential effect of RIP140 may involve differences in the
local chromatin environment of specific genes. First-pass
analysis of the predicted promoter regions of RIP140dependent target genes was unable to identify any cis-acting features that may account for differential sensitivity to
RIP140. We believe the RIP140-sensitive RA target genes
identified here may have pharmacologic importance during normal retinoid-based cancer therapy or prevention
[1,25]. It would also be interesting to know the number of
RIP140 sensitive genes that are direct RA-target genes.
Within the limits of the single RA dose and time-point
employed, RIP140-dependent genes can be placed in
three categories based on their expression profiles (Figure
5, 6 and 7). Some genes appeared super-induced or superrepressed with RIP140 repression, meaning they were
changed with RA to a greater degree in RIP140 siRNA cells
compared to control siRNA cells. Some genes were
induced with RA in RIP140 siRNA cells but unchanged by
RA in control siRNA cells. It may be predicted that this
subset of genes is regulated by RA in the control siRNA
cells at later time points. Some RA regulated genes in control cells were regulated basally in the siRNA RIP140 cells.
We propose that these genes are expressed in RIP140
siRNA cells due to the presence of previously sub-optimal
concentrations of retinoids in standard non-charcoal
stripped FBS media. Hence, from the data presented here
we propose the RIP140 plays a role in finetuning the RA
signal by either delaying the timing, decreasing the amplitude or decreasing the effective ligand concentration of
RAR activation (Figure 8C).
Recent microarray studies suggest extensive and early ligand-dependent repression of gene expression by nuclear
receptors [12,13]. However, the mechanism for such
repression is unclear. Ligand-dependent repressors like
RIP140 are candidate mediators of such repression. This is
particularly relevant for the steroid nuclear receptors such
as the estrogen, progesterone and glucocorticoid receptors. If RIP140 participates in this form of RAR "active
repression" one would expect that genes repressed by RA
would be de-repressed upon RIP140 silencing. Our data
does not support a widespread role for RIP140 in retinoid
receptor-mediated active repression. This conclusion is
consistent with the finding that RIP140 also inhibits glu-
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Figuredifferentially
Genes
4
expressed with RA in RIP140 siRNA treated NT2/D1 cells
Genes differentially expressed with RA in RIP140 siRNA treated NT2/D1 cells. Five of top six genes in which RAregulation was altered in RIP140 siRNA cells (Table 1) were confirmed by RT-PCR analysis. Samples used were the same as
those used in the microarray analysis (Figure 2C). Cells were mock transfected (no siRNA) or transfected with RIP140
siRNA#1 or RIP140 siRNA#2 prior to treatment with vehicle or 10 µM RA for 24 hours. In indicated samples (-RT) reverse
transcriptase was omitted to control for genomic DNA contamination.

cocorticoid receptor-mediated repression from a negative
GRE [26]. As with other nuclear receptor and coregulator
functions, active repression by RIP140 may be cell-, receptor- and context-specific.
While it is known that RIP140 modulates transcription
through repressing ligand-dependent nuclear receptors,
the possibility exists that RIP140 may function through
multiple mechanisms, including nuclear receptor-independent mechanisms. For example, a recent microarray
study reported a role for the coactivator, NCoA3/AIB1, in
receptor-independent activities, illustrating the diverse
functionality of coregulators and highlighting the need for
further elucidation of their role in gene transcription [27].
The microarray studies presented here were optimized to
investigate gene changes following RA treatment, making
it difficult to draw conclusions regarding the effects of
RIP140 on other nuclear receptors. Despite the inclusion
of normal sera media which may contain limiting quantities of ligand for other nuclear receptors, we were unable
to identify many RA-independent targets of RIP140. To
address this question, additional RIP140 siRNA array
studies should be performed with exogenous ligands for
other nuclear receptors.

A limited number of studies have been performed to
assess the global effect of RIP140 on gene expression.
Expression profiles were performed with murine embryonic fibroblasts in which RIP140 was deleted and reintroduced during adipocytic differentiation [28]. Another
study employed 3T3-L1 fibroblasts treated with RIP140
siRNA during adipocytic differentiation [29]. Genes identified to be regulated by RIP140 in these systems were
involved in glucose and fatty acid metabolism [28,29]. An
additional study profiled mouse ovaries from RIP140
knockout mice treated with or without human chorionic
gonadotropin and pregnant mare serum gonadotropin
[30]. There is little overlap in the RIP140-dependent genes
identified in these and our study. This is not surprising
since RIP140 likely regulates different sets of genes in different tissues based on the ligand/receptor under investigation and the distinct hormone sensitivities of the tissue.

Conclusion
The data demonstrates that RIP140 globally effects RAmediated gene expression and that RIP140 discriminates
between different classes of RA targets in the embryonal
carcinoma cancer stem cell model. Maintaining therapeutic doses of RA has proven difficult in the clinic [1,25].
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Table 2: Genes changed basally with RIP140 siRNA

Gene symbol

Gene description

FOLR1
RAB3B
SMAD5
MALAT1
DCX
B3GAT3
C14orf111
SMAD5
CUTL1
C18orf54
PTBP2
NRIP1
RSN
UHMK1
FNIP1
PCBP2
BAT2D1
FAM80B
UHMK1
XKR6
BACH1
LOC158863
GPD2
LOC552889
RBAK
ZFR
SLC39A14
UHMK1
HNRPU
PGGT1B
ZNF660
ZNF655
CDC42
ESCO1
UBE2W
HECTD1
UFM1
LOC641298
GCNT2
EDG7

Folate receptor 1 (adult)
RAB3B, member RAS oncogene family
SMAD family member 5
Metastasis associated lung adenocarcinoma 1 (non-coding RNA)
Doublecortex; lissencephaly, X-linked (doublecortin)
Beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I)
Chromosome 14 open reading frame 111
SMAD family member 5
Cut-like 1, CCAAT displacement protein (Drosophila)
Chromosome 18 open reading frame 54
Polypyrimidine tract binding protein 2
Nuclear receptor interacting protein 1
Restin (Reed-Steinberg expressed intermediate filament-associated)
U2AF homology motif (UHM) kinase 1
Folliculin interacting protein 1
Poly(rC) binding protein 2
BAT2 domain containing 1
Family with sequence similarity 80, member B
U2AF homology motif (UHM) kinase 1
XK, Kell blood group complex subunit-related family, member 6
BTB and CNC homology 1, basic leucine zip transcription factor 1
Hypothetical protein LOC158863
Glycerol-3-phosphate dehydrogenase 2 (mitochondrial)
Hypothetical LOC552889
RB-associated KRAB zinc finger
Zinc finger RNA binding protein
Solute carrier family 39 (zinc transporter), member 14
U2AF homology motif (UHM) kinase 1
Heterogen nuclear ribonucleoprotein U (scaffold attach factor A)
Protein geranylgeranyltransferase type I, beta subunit
Zinc finger protein 660
Zinc finger protein 655
Cell division cycle 42 (GTP binding protein, 25 kDa)
Establishment of cohesion 1 homolog 1 (S. cerevisiae)
Ubiquitin-conjugating enzyme E2W (putative)
HECT domain containing 1
Ubiquitin-fold modifier 1
PI-3-kinase-related kinase SMG-1 – like locus
Glucosaminyl (N-acetyl) transferase 2, (I blood group)
Endothelial differentiation, lysophosphatidic acid G-coupled recept

Fold
change
RIP140
siRNA/ctrl
siRNA

p-value

-4.65
-4.33
-3.28
-3.20
+2.82
-2.63
-2.62
-2.60
-2.52
-2.51
-2.48
-2.42
-2.36
-2.34
-2.34
-2.28
-2.28
-2.26
-2.26
-2.23
-2.22
-2.22
-2.22
-2.18
-2.17
-2.14
-2.14
-2.12
-2.12
-2.10
-2.09
-2.09
-2.08
-2.08
-2.07
-2.06
-2.05
+2.03
-2.03
-2.03

0.000730
0.005952
0.003862
0.000468
0.000682
0.005142
0.003088
0.006314
0.001457
0.003054
0.004811
0.011665
0.007189
0.009057
0.003628
0.001479
0.001042
0.008836
0.002063
0.001595
0.006338
0.001177
0.004723
0.014483
0.001749
0.001579
0.000483
0.000315
0.000802
0.002873
0.001916
0.011026
0.001266
0.002092
0.010394
0.012537
0.003571
0.000555
0.001021
0.013785

Gene list represents genes in scatter plot of Figure 3E; Group 3 (siRNA RIP140 vehicle) vs. Group 1 (control siRNA vehicle). Genes with p-value <
0.05 are ranked by fold-change. In bold is DCX the one gene changed basally in siRNA RIP140 cells that is not also changed by RA in control siRNA
cells. Also in bold is RIP140 (NRIP1). For genes with multiple probe sets, the probe set with the greatest differential expression was chosen.

Understanding the mechanisms that limit RA effectiveness may aid in developing new RA therapeutic strategies.
We propose that the combination of RIP140 gene silencing with RA treatment might enhance expression of
important RA target genes, thereby enhancing the therapeutic benefit of RA. Future studies should focus on pharmacologic modulation of RIP140 expression or activity as
a potential strategy to enhance the chemotherapeutic
action of retinoids.

Methods
Cell culture, siRNA and transfection protocols
The RA-sensitive human EC cell line, NT2/D1 is a clonal
line derived from a xenograft of Tera-2 cells [31]. Cells
were cultured in high glucose DMEM (Gibco) with 10%
FBS supplemented with glutamine and antibiotics.
Repression of RIP140 was achieved using three siRNAs
purchased from Dharmacon. RIP140siRNA#1 and
RIP140siRNA#2 have been previously described [22,23].
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Figure 5 cluster analysis of expression profile of RA-regulated genes in RIP140 siRNA cells
Hierarchical
Hierarchical cluster analysis of expression profile of RA-regulated genes in RIP140 siRNA cells. The 1115 genes
which were changed at least 1.8-fold with p-value < 0.01 in any of the four major groups were hierarchical clustered for similarity. The average expression value of Groups 2, 3 and 4 were compared to the average expression value of Group 1. Red
represents genes induced compared to Group 1, green represents genes repressed compared to Group 1. Highlighted clusters
are expanded to indicate individual genes and their expression pattern.

Page 12 of 18
(page number not for citation purposes)

Molecular Cancer 2007, 6:57

http://www.molecular-cancer.com/content/6/1/57

Figure 6 around medoids (PAM) analysis of RA-regulated genes
Partitioning
Partitioning around medoids (PAM) analysis of RA-regulated genes. The 1065 genes changed 1.5-fold or greater with
a p-value of < 0.001 were subjected to PAM analysis utilizing GeneSifter software as described in Methods. The number of
genes in each of the six clusters and the mean silhouette width (MSW) value for each cluster is indicated. Group 1 is control
siRNA vehicle. Group 2 is control siRNA RA. Group 3 is RIP140 siRNA vehicle. Group 4 is RIP140 siRNA RA. Expression
intensity values for a representative gene in each group is provided on left. Error bars are S.E.M.
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Figure siRNA
RIP140
7
effects RA target expression
RIP140 siRNA effects RA target expression. RT-PCR analysis of NT2/D1 cells transfected with scrambled siRNA or
RIP140 siRNA#1 and treated with DMSO (D) or 10 µM RA (R) for 24 hours. These samples are independent of those used for
microaray analysis. Genes were selected from array analysis or are known RA target genes. In indicated samples (-RT) reverse
transcriptase was omitted to control for genomic DNA contamination. Actin control is repeated for each figure for clarity. Pattern of genes for each figure are, super-induced with RIP140 siRNA (A and B), super-repressed with RIP140 siRNA (C), and
no change with RIP140 siRNA (D).
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genes silencing
RIP140
Figure
8
sensitizes NT2/D1 cells to low dose RA and accelerates and amplifies RA-dependent expression of RA-target
RIP140 silencing sensitizes NT2/D1 cells to low dose RA and accelerates and amplifies RA-dependent expression of RA-target genes. (A) Immunophenotypic FACS analysis for the established neuroectodermal marker A2B5 in NT2/
D1 cells transfected with 40 nM scrambled siRNA (Scbl) or RIP140 siRNA#1 or RIP140 siRNA#2 and treated for 4 days with
DMSO vehicle control or indicted dosages of RA. Data are presented as mean fluorescence (left) and percent positive cells
(right). (B) RT-PCR analysis of NT2/D1 cells transfected with 60 nM scrambled siRNA (Scbl) or RIP140 siRNA#1 and treated
with 10 µM RA for the indicated time points. Representative of two experiments. (C) Models of RIP140 regulation of RA signaling supported by the current study. See text for details.
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RIP140siRNA#1 is of sequence 5'-GAAGGAAGCUUUGCUAGCU-3' and corresponds to the human RIP140
cDNA starting 331 bp downstream of the ATG start
codon. RIP140siRNA#2 is of sequence 5'-CAAACAGGAUAGCACAUUA-3' and corresponds to human RIP140
cDNA starting 1986 bp downstream of the ATG start
codon. RIP140siRNA#3 is of sequence 5'-AACUGUGAGUAGCCUAUGA-3' and corresponds to the 3'-UTR of
RIP140 242 bp downstream of the stop codon. Controls
were the Scramble II siRNA or RISC-free siRNA from
Dharmacon. For microarray experiments, log-phase cells
were transfected with 90 nM siRNA using OligofectAMINE (Invitrogen) as described [22,23]. Briefly, 3.5
× 106 cells per 10 cm plate were transfected with 90 nM
siRNA for 16 h. 1 × 106 cells were then replated in normal
sera DMEM media per 10 cm dish and 24 hours later
treated with either 10 µM RA or DMSO for 24 hours
before harvesting for mRNA. For some indicated experiments, NT2/D1 cells were first incubated in charcoalabsorbed sera containing DMEM prior to transfection
with siRNA and treatment with indicated dosages of RA.
Reporter assays
The reporter, RARE-TK-Luc, and the expression plasmid
pSG5-HAhRIP140 have been previously described [2123]. Cells were plated at 1.5 × 105 cells per well of a sixwell plate and transfected with Polyfect (Qiagen) according to the manufacturer's directions. Tranfections were
performed in triplicate for each condition with a final
concentration of 0.375 µg RARE-TK-Luc, 0.375 µg pRLTK, 0.75 µg of either pSG5-insertless or pSG5HAhRIP140, and 50 nM of control or RIP140 siRNA. Cells
were exposed to transfection reagent for 16 hours and
then washed and cultured in indicated dosages of RA or
the vehicle, DMSO. Cells were harvested 48 hours following transfection and Dual Luciferase Reporter analysis was
performed (Promega). Luciferase activity was normalized
against renilla activity and reported as the average of triplicate transfections with similar results obtained in at least
two independent experiments.
Northern and RT-PCR analysis
Total RNA was harvested using TriReagent (Invitrogen).
Northern hybridizations for RARβ and RIP140 were performed with 5 µg RNA as previously described [22].
Expression levels of RA-target genes were assessed by
semi-quantitative RT-PCR. The cDNA was synthesized
using Superscript II RT from 5 µg total RNA. PCR analysis
was performed with Taq polymerase (Denville) to varying
cycle numbers within the linear range as previously
described [22]. The sequence of primers are available
upon request.

http://www.molecular-cancer.com/content/6/1/57

Immunophenotypic analyses
Indirect fluorescence activated cell sorter (FACS) analysis
to evaluate RA-induced neuronal differentiation of NT2/
D1 cells was performed using established techniques [32].
Briefly, NT2/D1 cells were harvested by trypsinization and
incubated with antibody to the cell surface antigen A2B5
or with isotype-matched monoclonal antibody as controls. The A2B5 antibody recognizes a neuronal epitope
on RA-treated NT2/D1 cells and was prepared from hybridoma cultures purchased from ATCC. The cells were indirectly assayed with FITC-conjugated goat-anti-mouse
antibody, and fluorescence was measured as described
[32]. Mean peak fluorescent values and the percentage of
positive cells were measured for the entire population. At
least 1 × 104 cells were analyzed per assay.
Microarray analysis
Total RNA was purified using RNeasy columns (Qiagen).
Hybridizations were performed according to Affymetrix
guidelines at the Dartmouth College Microarray Shared
Resource using an Affymetrix GeneChip Workstation.
Biotin-labeled cRNA was generated from 5 µg of total
RNA and hybridized to the Human Genome (HG) U133
Plus 2.0 chip which contains over 54,000 probe sets.
Unless specifically stated we will refer to each probe set as
a "gene". As described in Figure 2A, a total of 12 hybridizations were performed comprising 12-independent biologic samples organized into four groups of three. This
data is available at the GEO website under Accession
GSE7500 and conforms to MIAME guidelines. Raw data
from each hybridization was normalized by RMA, background corrected and filtered for present using GeneSifter
software (vizX Labs). As a further filter, any gene that
showed a 1.5-fold or greater difference amongst the three
samples comprising Group 1 (the siRNA controls) were
eliminated from further analysis. The remaining 52,270
probe sets were then analyzed by GeneSifter software.
Pairwise comparisons between groups were performed
using t-test with p-value and cutoffs as indicated. For hierarchical cluster analysis genes changed 1.8 fold or greater
between any of the four groups with p-value < .01 (1115
genes) were clustered via the Cluster program by Michael
Eisen using a correlation metric for similarity matrix and
average linkage clustering [33]. The clustered data was visualized by Tree-View software. Genes were also divided
into clusters using partitioning around medoids (PAM)
analysis from the GeneSifter package. Genes changed 1.5fold or greater with a p-value of < .001 (1065 genes) were
used for this analysis using the correlation metric for similarity. The number of clusters (six) was chosen empirically to obtain the best mean silhouette value of 0.560.

Abbreviations used
NRIP1, nuclear receptor interacting protein 1; RA, retinoic
acid; EC, embryonal carcinoma; RAR, retinoic acid recep-
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tor; RXR, retinoid X receptor; NcoR, nuclear receptor corepressor 1; SMRT, silencing mediator for retinoid and
thyroid hormone receptor; CTBP, c-terminal binding protein.
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